{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:05:40Z","timestamp":1773353140247,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To compare the time to initiation of first therapeutic treatment and the outcomes of controlled ovarian stimulation (COS) in breast cancer patients undergoing fertility preservation (FP) in the neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC) treatment settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study involving patients with stage 1\u20133 breast cancer treated with NAC\/AC, who underwent FP with random-start COS, between 2015\u20132023. Baseline, oncologic and COS characteristics and outcomes were collected. Time points related to cancer diagnosis, FP, and first oncologic intervention (surgery or chemotherapy) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      70 NAC-treated patients were compared to 42 AC-treated patients. Groups were similar in terms of age, marital status, parity and BMI. NAC-treated patients had more advanced disease, more often with lymph node involvement. Median time from diagnosis to FP consult (17 vs 30 days) and to stimulation start (22 vs 59 days) was significantly shorter for NAC-treated patients. Median time from diagnosis to first therapeutic intervention was slightly longer for NAC-treated patients (45 vs 41 days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Stimulation characteristics were comparable apart from a less frequent use of hCG trigger among NAC-treated patients (4% vs 16%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). First stimulation cycle outcomes such as peak E2 levels, number of retrieved oocytes and fertilization rate were similar, though median number of M2 oocytes was higher in NAC- treated patients (11 vs 8,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Expedited patient care at the neoadjuvant setting led to a statistically significant, yet clinically minimal, delay of cancer therapy. Neither oncologic treatment timelines nor FP outcomes were compromised in the NAC setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10815-026-03812-6","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:29:57Z","timestamp":1771590597000},"page":"923-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fertility preservation using controlled ovarian stimulation in breast cancer: a comparative study of neoadjuvant and adjuvant settings"],"prefix":"10.1007","volume":"43","author":[{"given":"Moran","family":"Shapira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Berkovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Safrai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jigal","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adva","family":"Aizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dror","family":"Meirow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raoul","family":"Orvieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"2","key":"3812_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06113-0","volume":"151","author":"C Xia","year":"2025","unstructured":"Xia C, et al. Global evolution of breast cancer incidence in childbearing-age women aged 15-49 years: a 30-year analysis. J Cancer Res Clin Oncol. 2025;151(2): 75.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3812_CR2","doi-asserted-by":"publisher","first-page":"e2353331","DOI":"10.1001\/jamanetworkopen.2023.53331","volume":"7","author":"S Xu","year":"2024","unstructured":"Xu S, et al. Breast cancer incidence among US women aged 20 to 49 years by race, stage, and hormone receptor status. JAMA Netw Open. 2024;7(1):e2353331.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3812_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1158\/1078-0432.CCR-11-2599","volume":"18","author":"HA Azim Jr.","year":"2012","unstructured":"Azim HA Jr., et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18(5):1341\u201351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3812_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13058-016-0736-y","volume":"18","author":"L Chollet-Hinton","year":"2016","unstructured":"Chollet-Hinton L, et al. Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. Breast Cancer Res. 2016;18(1):79.","journal-title":"Breast Cancer Res"},{"key":"3812_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jss.2023.12.023","volume":"296","author":"E Graham","year":"2024","unstructured":"Graham E, et al. Young age as a predictor of chemotherapy recommendation and treatment in breast cancer: a national cancer database study. J Surg Res. 2024;296:155\u201364.","journal-title":"J Surg Res"},{"issue":"11","key":"3812_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","volume":"33","author":"S Paluch-Shimon","year":"2022","unstructured":"Paluch-Shimon S, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). Ann Oncol. 2022;33(11):1097\u2013118.","journal-title":"Ann Oncol"},{"key":"3812_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-319-16366-6_2","volume":"862","author":"PA Ganz","year":"2015","unstructured":"Ganz PA, Bower JE, Stanton AL. Special issues in younger women with breast cancer. Adv Exp Med Biol. 2015;862:9\u201321.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"3812_CR8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.fertnstert.2012.11.057","volume":"99","author":"K Chung","year":"2013","unstructured":"Chung K, et al. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril. 2013;99(6):1534\u201342.","journal-title":"Fertil Steril"},{"key":"3812_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00871","author":"I Jackson","year":"2025","unstructured":"Jackson I, et al. Treatment patterns, trends, and outcomes of neoadjuvant chemotherapy use among patients with early-stage invasive triple-negative breast cancer. JCO Oncol Pract. 2025. https:\/\/doi.org\/10.1200\/OP-24-00871.","journal-title":"JCO Oncol Pract"},{"issue":"10","key":"3812_CR10","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1245\/s10434-015-4714-x","volume":"22","author":"PJ Graham","year":"2015","unstructured":"Graham PJ, et al. Neoadjuvant Chemotherapy for Breast Cancer, Is Practice Changing? A Population-Based Review of Current Surgical Trends. Ann Surg Oncol. 2015;22(10):3376\u201382.","journal-title":"Ann Surg Oncol"},{"key":"3812_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1200\/GO.22.00008","volume":"6","author":"A Hershlag","year":"2020","unstructured":"Hershlag A, Mullin C, Bristow SL. Is fertility preservation feasible and safe with neoadjuvant therapy for breast cancer? JCO Glob Oncol. 2020;6:356\u20139.","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"3812_CR12","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00404-021-05985-0","volume":"303","author":"M Kappy","year":"2021","unstructured":"Kappy M, et al. Fertility preservation for cancer patients: treatment gaps and considerations in patients\u2019 choices. Arch Gynecol Obstet. 2021;303(6):1617\u201323.","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"3812_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.fertnstert.2011.12.008","volume":"97","author":"J Kim","year":"2012","unstructured":"Kim J, et al. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer. Fertil Steril. 2012;97(3):671\u20136.","journal-title":"Fertil Steril"},{"issue":"3","key":"3812_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.fertnstert.2024.10.014","volume":"123","author":"M Shapira","year":"2025","unstructured":"Shapira M, et al. Long-term safety of controlled ovarian stimulation for fertility preservation before chemotherapy treatment in patients with breast cancer. Fertil Steril. 2025;123(3):477\u201387.","journal-title":"Fertil Steril"},{"key":"3812_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2022.06.048","volume":"173","author":"RA Anderson","year":"2022","unstructured":"Anderson RA, et al. Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy. Eur J Cancer. 2022;173:113\u201322.","journal-title":"Eur J Cancer"},{"issue":"18","key":"3812_CR16","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","volume":"388","author":"AH Partridge","year":"2023","unstructured":"Partridge AH, et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N Engl J Med. 2023;388(18):1645\u201356.","journal-title":"N Engl J Med"},{"issue":"7","key":"3812_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cncr.33342","volume":"127","author":"PD Poorvu","year":"2021","unstructured":"Poorvu PD, et al. Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. Cancer. 2021;127(7):1021\u20138.","journal-title":"Cancer"},{"key":"3812_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113500","volume":"198","author":"IT Rubio","year":"2024","unstructured":"Rubio IT, et al. EUSOMA quality indicators for non-metastatic breast cancer: An update. Eur J Cancer. 2024;198: 113500.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3812_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamasurg.2013.1680","volume":"148","author":"EC Smith","year":"2013","unstructured":"Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race\/ethnicity. JAMA Surg. 2013;148(6):516\u201323.","journal-title":"JAMA Surg"},{"issue":"9","key":"3812_CR20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1634\/theoncologist.2019-0744","volume":"25","author":"D de Melo Gagliato","year":"2020","unstructured":"de Melo Gagliato D, et al. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast cancer. Oncologist. 2020;25(9):749\u201357.","journal-title":"Oncologist"},{"issue":"13","key":"3812_CR21","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.1007\/s00432-023-05060-y","volume":"149","author":"ME Hatzipanagiotou","year":"2023","unstructured":"Hatzipanagiotou ME, et al. Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer? J Cancer Res Clin Oncol. 2023;149(13):11941\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3812_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10815-023-02739-6","volume":"40","author":"I Sellami","year":"2023","unstructured":"Sellami I, et al. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM. J Assist Reprod Genet. 2023;40(3):473\u201380.","journal-title":"J Assist Reprod Genet"},{"issue":"10","key":"3812_CR23","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1093\/humrep\/dex276","volume":"32","author":"JM Letourneau","year":"2017","unstructured":"Letourneau JM, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod. 2017;32(10):2123\u20139.","journal-title":"Hum Reprod"},{"issue":"1","key":"3812_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-017-4288-3","volume":"165","author":"AJ Chien","year":"2017","unstructured":"Chien AJ, et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017;165(1):151\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"3812_CR25","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/humrep\/deaa029","volume":"35","author":"A Marklund","year":"2020","unstructured":"Marklund A, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020;35(4):929\u201338.","journal-title":"Hum Reprod"},{"issue":"1","key":"3812_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/humrep\/deac242","volume":"38","author":"Y Esmaeilian","year":"2023","unstructured":"Esmaeilian Y, et al. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients. Hum Reprod. 2023;38(1):113\u201324.","journal-title":"Hum Reprod"},{"issue":"6","key":"3812_CR27","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ajo.13721","volume":"63","author":"S Sii","year":"2023","unstructured":"Sii S, et al. Controlled ovarian hyperstimulation in breast cancer patients: Does oestrogen receptor status make a difference? Aust N Z J Obstet Gynaecol. 2023;63(6):774\u20139.","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"10","key":"3812_CR28","doi-asserted-by":"publisher","first-page":"102215","DOI":"10.1016\/j.jogoh.2021.102215","volume":"50","author":"R Cioffi","year":"2021","unstructured":"Cioffi R, et al. Do stage and grade of malignancy impact fertility preservation in breast cancer patients? J Gynecol Obstet Hum Reprod. 2021;50(10):102215.","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"6","key":"3812_CR29","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/01443615.2019.1674791","volume":"40","author":"A Ben-Haroush","year":"2020","unstructured":"Ben-Haroush A, et al. Does \u201cdual trigger\u201d increase oocyte maturation rate? J Obstet Gynaecol. 2020;40(6):860\u20132.","journal-title":"J Obstet Gynaecol"},{"issue":"7","key":"3812_CR30","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/humrep\/deaa107","volume":"35","author":"J Haas","year":"2020","unstructured":"Haas J, et al. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study. Hum Reprod. 2020;35(7):1648\u201354.","journal-title":"Hum Reprod"},{"issue":"Suppl 1","key":"3812_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12958-024-01332-5","volume":"23","author":"R Orvieto","year":"2025","unstructured":"Orvieto R. Triggering final follicular maturation for IVF cycles. Reprod Biol Endocrinol. 2025;23(Suppl 1):12.","journal-title":"Reprod Biol Endocrinol"},{"issue":"7","key":"3812_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clbc.2025.06.003","volume":"25","author":"V Turan","year":"2025","unstructured":"Turan V, et al. Utilization and fertility preservation outcomes in women undergoing embryo cryopreservation before breast cancer treatment: a meta-analysis. Clin Breast Cancer. 2025;25(7):617-624 e1.","journal-title":"Clin Breast Cancer"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-026-03812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-026-03812-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-026-03812-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:18:59Z","timestamp":1773314339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-026-03812-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1007\/s10815-026-03812-6","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional ethics committee approval was obtained for the study (SMC 9383\u201322).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}